13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • AK105-101

    Acronym: 

    AK105-101

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Phase 1a/1b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and ntitumor activity of AK105 in subjects with advanced solid tumors

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream Solid Tumours
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid Tumours
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase 1a/1b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and antitumor activity of AK105 in subjects with advanced solid tumors

    Lay Summary

    A Phase 1a/1b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and ntitumor activity of AK105 in subjects with advanced solid tumors

    Sponsor / Cooperative group

    AkesoBio

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting